Find FDA Investigational New Drug (IND) Submissions for Cardiology/Vascular Diseases

Lead Product(s): MAT9001

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: BTIG

Deal Size: $30.0 million Upfront Cash: Undisclosed

Deal Type: IPO January 09, 2020

Details:

Matinas BioPharma anticipates using the net proceeds from the offering primarily for ongoing development for its product candidates, namely MAT9001, and its lipid nano-crystal (“LNC”) platform delivery technology